# TROPHY-U-01 (NCT03547973)

> Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

No report yet. It can be ordered.

- Drugs tested: sacituzumab govitecan; sacituzumab govitecan plus pembrolizumab; sacituzumab govitecan plus cisplatin plus avelumab
- Indication: unresectable locally advanced or metastatic urothelial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03547973
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Metastatic Urothelial Cancer
- Interventions: Sacituzumab Govitecan-hziy; Pembrolizumab; Cisplatin; Avelumab; Zimberelimab; Carboplatin; Gemcitabine; Domvanalimab; Enfortumab Vedotin
- Enrollment: 502
- Primary outcome: Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6)
- Primary outcome: Progression free survival (PFS) Based on Central Review by RECIST 1.1 criteria (Cohort 5)
- Primary outcome: ORR Based on Investigator Review by RECIST 1.1 Criteria (Cohort 7)
- Primary outcome: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) (Cohort 7)
- Primary outcome: Percentage of Participants Experiencing any Clinically Significant Laboratory Abnormalities (Cohort 7)

## Some of the questions raised in the 40 most recent indexed sources

_Automated from the 40 newest of 158 indexed sources (Feb 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether the sacituzumab govitecan, enfortumab vedotin and zimberelimab triplet improves on enfortumab vedotin plus pembrolizumab
- How tolerable the triplet is, and how often enfortumab vedotin has to be stopped
- Whether the triplet's early findings hold with longer follow-up and in larger randomized testing

## Indexed commentary on TROPHY-U-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 108 posts on X
- 25 podcast episodes
- 24 YouTube videos
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=trophy-u-01-nct03547973

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03547973", "email": "<work email>"}; the inbox owner confirms by the emailed link.